Orchid Pharma: NCLT Dismisses DBS Bank's Lease Rent Claim
NCLT Chennai dismissed DBS Bank's application for lease rent during CIRP. The order, pronounced on April 02, 2026, and made available on April 10, 2026, has no quantifiable financial impact on Orchid Pharma.
The announcement explicitly states that the impact on financial, operational, or other activities of the listed entity is 'Nil'. Therefore, the impact is considered low.
The dismissal of the claim by DBS Bank is a positive development for Orchid Pharma as it resolves a legal dispute and has no negative financial impact.
Orchid Pharma Limited announced that the National Company Law Tribunal (NCLT), Chennai Bench, has dismissed an application filed by DBS Bank (formerly Lakshmi Villas Bank) concerning a claim for lease rent during the Corporate Insolvency Resolution Process (CIRP) period. The order was pronounced on April 02, 2026, and made available on April 10, 2026.
The application by DBS Bank sought relief under various sections of the Insolvency and Bankruptcy Code, 2016, and related regulations, claiming lease dues and Insolvency Resolution Process Costs for the CIRP period. The NCLT, after hearing the matter, dismissed the Interim Application (IA) filed by DBS Bank.
The company has stated that the impact of this dismissal on its financial, operational, or other activities is nil. This development is a follow-up to a previous intimation dated September 27, 2023, and is in accordance with Regulation 30 of SEBI Listing Obligations and Disclosure requirements.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under corporate insolvency resolution process. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.